Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Lung Cancer Detection by Measuring Monocyte Activity (EDLC)

16. marts 2014 opdateret af: Carmel Medical Center

Lung Cancer Detection and Staging by Extracellular Monitoring of Metabolic Activity Profiles of Peripheral Blood Mononuclear Cells (PBMC)

Purpose: To evaluate the performance of Extracellular Monitoring of Metabolic Activity Profiles of Peripheral Blood Mononuclear Cells (PBMC) analysis method in identifying lung cancer.

The study population will include a total of 950 participants, patients with lung cancer before any treatment, and healthy and COPD patients as a control group.

Studieoversigt

Status

Ukendt

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The purpose of the study is to evaluate the performance of Extracellular Monitoring of Metabolic Activity Profiles of Peripheral Blood Mononuclear Cells (PBMC) analysis method in identifying lung cancer.

The analysis method described in this protocol is a novel simple plausible immunological approach which is non-invasive, high throughput, real-time quantitative monitoring of metabolic activity (MA) profiles of fresh Peripheral Blood Mononuclear Cells (PBMC) in response to various reagents at different concentrations.

Study Design Prospective, three groups, open, comparative, controlled study. No. of Sites One Study Population Man and Women aged 18 - 90 years old. No. of Subjects A total of 950 completed, evaluated subjects will be enrolled in this study.

The groups sample size is as follows:

Group 1 - 75 subjects Group 2 - 75 subjects Group 3 - 150 subjects Group 4 - 650 subjects

Primary End Point 1. Positive and negative diagnosis (scored 0/1 dichotomously) in accordance with clinical data collected

Data Analysis and Statistics Multiple MA profiles including a huge number of MA rates values are obtained for each subject. In order to develop a dynamic clinical analysis that is updated with every new subject, and to extract patterns from this large data base, The research team designed computer programming using Data Mining tools, which combine methods from statistics and artificial intelligence with database management.

Blood test will be perform from each subject. The blood sample in eah subject will be compare to his status : healthy non smoker, healthy smoker, COPD or diagnosed with lung cancer.

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

950

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Haifa, Israel, 34362
        • Carmel Medical Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 90 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria

  1. Subject signed the informed consent.
  2. Subject is between 18 to 90 years old.
  3. Lung cancer diagnosis before any treatment

Exclusion Criteria

  1. Lung cancer patients
  2. Subject has been previously treated for any type of malignant or benign tumor (for example: colon or uterus polyps removal).
  3. Subject has active infection or inflammation determined clinically at screening.
  4. Subject is currently treated with concomitant medication related directly or can affect the immune system.
  5. Subject lactating or undergoing fertility treatment.
  6. Subject has impaired judgment.
  7. Known positive HIV, hepatitis B, or hepatitis C, autoimmune disease.
  8. Known history of a significant medical disorder, which in the investigators' judgment contraindicates the patient's participation.
  9. Known hypersensitivity and/or allergy
  10. Drug or alcohol abuse (by history).
  11. Subject is participating in any other clinical trial, drug or device study within 30 days prior sample collection
  12. Relatives of the study investigators or employees of the study investigators are not allowed to participate in the study

    -

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Diagnostisk
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Andet: lung cancer diagnosis

4 arms will be included in the study:

The groups sample size is as follows:

Group 1 - Healthy non smoker- 75 subjects Group 2 - Healthy smoker- 75 subjects Group 3 - Patients diagnosed as having COPD- 150 subjects Group 4 - Patients with diagnosis of lung cancer- 650 subjects

A blood test will be taken from each patient.

a blood test will be taken from each patient

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Positive and negative diagnosis (scored 0/1 dichotomously) of lung cancer
Tidsramme: 1 year
1 year

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Yochai Adir, MD, Carmel Medical Center

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. april 2014

Primær færdiggørelse (Forventet)

1. januar 2020

Studieafslutning (Forventet)

1. januar 2021

Datoer for studieregistrering

Først indsendt

10. marts 2014

Først indsendt, der opfyldte QC-kriterier

16. marts 2014

Først opslået (Skøn)

18. marts 2014

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

18. marts 2014

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. marts 2014

Sidst verificeret

1. marts 2014

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • CMC-13-0105-CTIL

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Lungekræft

Kliniske forsøg med Blood test

3
Abonner